Skip to main content
SpringerLink
Log in

In vitro activity of grepafloxacin againstHaemophilus influenzae andMoraxella catarrhalis

  • Letters
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Imada T, Miyazaki S, Nishida M, Yamaguchi K, Goto S: In-vitro and in vivo antibacterial activities of a new quinolone OPC-17116. Antimicrobial Agents and Chemotherapy (1992) 36:573–579.

    PubMed  Google Scholar 

  2. Miyamoto H, Yamashita H, Ueda H, Tamaoka H, Ohmori K, Nakagawa K: Synthesis and biological properties of substituted 1,4-dihydro-5-methyl-4-oxo-3-quinolinecarboxylic acids. Bioorganic and Medicinal Chemistry (1995) 3:1699–1706.

    PubMed  Google Scholar 

  3. Pankuch GA, Jacobs MR, Appelbaum PC: Activity of CP 99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. Journal of Antimicrobial Chemotherapy (1995) 35:230–232.

    PubMed  Google Scholar 

  4. Efthymiopoulos C, Bramer SL, Maroli, A: Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males. Clinical Pharmacokinetics (1997) 33, Supplement 1:1–8.

    Google Scholar 

  5. Cook PJ, Andrews JM, Wise R, Honeybourne D, Moudgil H: Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments. Journal of Antimicrobial Chemotherapy (1995) 35:317–326.

    PubMed  Google Scholar 

  6. Wakebe H, Imada T, Yoneda H, Mukai F, Ohguro K, Ohmori K, Tamaoka H, Yabuuchi Y: Evaluation of OPC-17116 against important pathogens that cause respiratory tract infections. Antimicrobial Agents and Chemotherapy (1994) 38:2340–2345.

    PubMed  Google Scholar 

  7. Bale MJ, Jones RN, Erwin ME: Minimum inhibitory concentration quality-control guidelines for biapenem, DU-6859a, FK-037, levofloxacin, grepafloxacin and ceftizoxime when using National Committee for Clinical Laboratory Standards susceptibility test methods. Diagnostic Microbiology and Infectious Disease (1994) 19:65–68.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Microbiology, St. Bartholomew's and the Royal London School of Medicine and Dentistry, Turner Street, El 2AD, Whitechapel, London, UK

    J. P. Maskell, A. C. Whiley & A. M. Sefton

Authors
  1. J. P. Maskell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. C. Whiley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. M. Sefton
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maskell, J.P., Whiley, A.C. & Sefton, A.M. In vitro activity of grepafloxacin againstHaemophilus influenzae andMoraxella catarrhalis . Eur. J. Clin. Microbiol. Infect. Dis. 17, 293–295 (1998). https://doi.org/10.1007/BF01699991

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01699991

Keywords

Search

Navigation